Hepatotoxicity and drug interactions in liver transplant candidates and recipients

Neehar D. Parikh, Josh Levitsky*

*Corresponding author for this work

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

In this article the medications that have been shown to increase rates of drug-induced liver injury in patients with cirrhosis and the important drug-drug interactions in recipients of liver transplantation are reviewed. In general, the risk of drug-induced liver injury in patients with cirrhosis does not seem to be higher when compared with the noncirrhotic population. There are, however, 2 classes of agents that have been implicated-medications used to treat tuberculosis and medications used to treat human immunodeficiency virus infection. However, with careful monitoring, even significant interactions can be effectively managed.

Original languageEnglish (US)
Pages (from-to)737-747
Number of pages11
JournalClinics in Liver Disease
Volume17
Issue number4
DOIs
StatePublished - Nov 1 2013

Fingerprint

Chemical and Drug Induced Liver Injury
Drug Interactions
Fibrosis
Liver
Virus Diseases
Liver Transplantation
Tuberculosis
HIV
Pharmaceutical Preparations
Population
Transplant Recipients

Keywords

  • Calcineurin
  • DILI
  • Immunosuppressives
  • Medication

ASJC Scopus subject areas

  • Hepatology

Cite this

@article{1c5eb38e1cb541e893f08b71f68afd42,
title = "Hepatotoxicity and drug interactions in liver transplant candidates and recipients",
abstract = "In this article the medications that have been shown to increase rates of drug-induced liver injury in patients with cirrhosis and the important drug-drug interactions in recipients of liver transplantation are reviewed. In general, the risk of drug-induced liver injury in patients with cirrhosis does not seem to be higher when compared with the noncirrhotic population. There are, however, 2 classes of agents that have been implicated-medications used to treat tuberculosis and medications used to treat human immunodeficiency virus infection. However, with careful monitoring, even significant interactions can be effectively managed.",
keywords = "Calcineurin, DILI, Immunosuppressives, Medication",
author = "Parikh, {Neehar D.} and Josh Levitsky",
year = "2013",
month = "11",
day = "1",
doi = "10.1016/j.cld.2013.07.013",
language = "English (US)",
volume = "17",
pages = "737--747",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "4",

}

Hepatotoxicity and drug interactions in liver transplant candidates and recipients. / Parikh, Neehar D.; Levitsky, Josh.

In: Clinics in Liver Disease, Vol. 17, No. 4, 01.11.2013, p. 737-747.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Hepatotoxicity and drug interactions in liver transplant candidates and recipients

AU - Parikh, Neehar D.

AU - Levitsky, Josh

PY - 2013/11/1

Y1 - 2013/11/1

N2 - In this article the medications that have been shown to increase rates of drug-induced liver injury in patients with cirrhosis and the important drug-drug interactions in recipients of liver transplantation are reviewed. In general, the risk of drug-induced liver injury in patients with cirrhosis does not seem to be higher when compared with the noncirrhotic population. There are, however, 2 classes of agents that have been implicated-medications used to treat tuberculosis and medications used to treat human immunodeficiency virus infection. However, with careful monitoring, even significant interactions can be effectively managed.

AB - In this article the medications that have been shown to increase rates of drug-induced liver injury in patients with cirrhosis and the important drug-drug interactions in recipients of liver transplantation are reviewed. In general, the risk of drug-induced liver injury in patients with cirrhosis does not seem to be higher when compared with the noncirrhotic population. There are, however, 2 classes of agents that have been implicated-medications used to treat tuberculosis and medications used to treat human immunodeficiency virus infection. However, with careful monitoring, even significant interactions can be effectively managed.

KW - Calcineurin

KW - DILI

KW - Immunosuppressives

KW - Medication

UR - http://www.scopus.com/inward/record.url?scp=84884967039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884967039&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2013.07.013

DO - 10.1016/j.cld.2013.07.013

M3 - Review article

C2 - 24099028

AN - SCOPUS:84884967039

VL - 17

SP - 737

EP - 747

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 4

ER -